partner with kode
work with Kode Biotech
Custom FSL constructs, licensing, research collaboration and Kode Immunoeducer partnerships.
Partner with Kode: six ways to work together
Custom FSL constructs
If your molecule is not in our catalogue, talk to us, as we often make bespoke constructs.
Start an enquiry ↓ About FSL constructs →License Kode Technology
Kode Biotech owns Kode Technology and licenses it to companies developing new products.
Discuss a licence ↓ The Kode Group →Research collaboration
Working on cell surfaces, antibodies or glycans? Talk to us about using Kode Technology in your research.
Get in touch ↓ Science and Publications →Human cancer KIEs
Partner with Equitable Oncology, which coordinates the clinical, scientific and philanthropic partnerships that advance K5K and AGI-134.
Equitable Oncology → About KIEs →Veterinary cancer KIEs
Partner with Kode Veterinary Sciences on developing and commercialising Kv9.
Kode Veterinary Sciences → Kv9 →Buy research FSLs
Catalogue FSL constructs and glycoconjugates from GlycoNZ (glyconz.com) and Merck MilliporeSigma.
glyconz.com →Custom FSL constructs: how a project works
Partner with Kode: technologies available for licence or acquisition
Kode Technology has uses beyond our own programmes. The technologies below are available to partners. The information here is non-confidential; further data are available under a confidentiality agreement.
Alpha-Gal oncolytic virus
An oncolytic virus that carries the gene for the enzyme α1,3-galactosyltransferase. Tumour cells it infects display the alpha-Gal epitope, which the body's natural anti-Gal antibodies recognise.
- Stage
- Patent rights. Kode Agalimmune is not developing the programme itself.
- IP
- Granted in the US (US 12,023,362 B2), Europe (EP 3280798 B1), Canada, Japan, Korea, India, Israel, Mexico, Russia and Hong Kong
- Sought
- Acquisition of the patent family
Antimicrobial coatings for dressings and implants
FSL constructs coat almost any surface (metals, plastics, ceramics, polymers and nanofibres) in seconds to minutes, by dipping, spraying, painting or printing. They can hold antimicrobial agents at the surface through repeated washing.
- Evidence
- In a proof-of-concept study, a wound dressing given an FSL antimicrobial coating stayed sterile after challenge with about 3 million S. aureus; results were similar with S. epidermidis, P. aeruginosa and E. coli. Coatings have also been shown on PVC, nanofibres and nanomembranes.
- Stage
- Proof of concept
- Sought
- Licence by field (wound care, medical devices) or co-development
Liposome modification
FSL constructs insert into liposomes during or after manufacture without changing their size, shape or membrane organisation. They add surface molecules for targeting or stability.
- Evidence
- A doctoral study of liposome labelling found FSL constructs "very effective at labelling liposomes", with no significant change to liposome size, morphology or stability (Campbell, PhD thesis, Auckland University of Technology, 2023). A 100 nm liposome carries about 640 FSL constructs. FSL-PEG and FSL-Zero have been used to stabilise anticancer liposomes loaded with a prodrug (Tretiakova et al., Colloids and Surfaces B, 2018). Vesicles carrying FSL constructs have been taken up by cells through lectin binding.
- Stage
- Research
- Sought
- Research collaboration or licence